Skip to main content
SpringerLink
Log in

Prevention and Treatment of Botulism

  • Chapter
  • First Online:
Molecular Aspects of Botulinum Neurotoxin

Part of the book series: Current Topics in Neurotoxicity ((Current Topics Neurotoxicity,volume 4))

Abstract

Concerns regarding botulinum neurotoxins (BoNTs) as biowarfare and bioterrorist agents have generated interest in developing medical countermeasures for protection against the neurotoxins. Efforts have focused on improvements in the available vaccines and antisera and de novo discovery of pharmacological inhibitors of toxin action. This chapter reviews the various approaches taken to develop next-generation vaccines, antitoxins and pharmacological treatments against intoxication by the BoNTs. The historical progression, current status and future trends are described.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Adler M (2006) Inhalation toxicology of botulinum neurotoxin. In: Salem H, Katz SA (eds) Inhalation toxicology, 2nd edn. Taylor & Francis, Boca Raton, pp 963–972

    Google Scholar 

  2. Adler M, Nicholson JD (2008) Evaluation of toosendanin as a botulinum neurotoxin antagonist. Botulinum J 1:208–218

    Google Scholar 

  3. Adler M, Oliveira AC, Albuquerque EX, Mansour NA, Eldefrawi AT (1979) Reaction of tetraethylammonium with the open and closed conformation of the acetylcholine receptor ionic channel complex. J Gen Physiol 74:129–152

    CAS  PubMed  Google Scholar 

  4. Adler M, Scovill J, Parker G, Lebeda FJ, Piotrowski J, Deshpande SS (1995) Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations. Toxicon 33:527–537

    CAS  PubMed  Google Scholar 

  5. Adler M, MacDonald DA, Sellin LC, Parker GW (1996) Effect of 3,4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin. Toxicon 34:237–249

    CAS  PubMed  Google Scholar 

  6. Adler M, Dinterman RE, Wannemacher RW (1997) Protection by the heavy metal chelator N, N, N’, N’-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) against the lethal action of botulinum neurotoxin A and B. Toxicon 35:1089–1100

    CAS  PubMed  Google Scholar 

  7. Adler M, Nicholson JD, Cornille F, Hackley BE Jr (1998) Efficacy of a novel metalloprotease inhibitor on botulinum neurotoxin B activity. FEBS Lett 429:234–238

    CAS  PubMed  Google Scholar 

  8. Adler M, Shafer H, Hamilton T, Petrali JP (1999) Cytotoxic actions of the heavy metal chelator TPEN on NG108-15 neuroblastoma-glioma cells. NeuroToxicology 20:571–582

    CAS  PubMed  Google Scholar 

  9. Adler M, Capacio B, Deshpande SS (2000) Antagonism of botulinum toxin A-mediated muscle paralysis by 3,4-diaminopyridine delivered via osmotic minipumps. Toxicon 38:1381–1388

    CAS  PubMed  Google Scholar 

  10. Adler M, Keller JE, Sheridan RE, Deshpande SS (2001) Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in the rat EDL muscle. Toxicon 39:233–243

    CAS  PubMed  Google Scholar 

  11. Adler M, Deshpande S, Mangel P, Nicholson J, Apland J (2008) Reversal of BoNT/A-mediated paralysis by 3,4-diaminopyridine and roscovitine in mouse phrenic nerve-hemidiaphragm preparations. 45th Annual Interagency Botulinum Research Coordinating Committee Meeting, Philadelphia, PA

    Google Scholar 

  12. Adler M, Deshpande SS, Apland JP (2010) Simultaneous or sequential administration of botulinum neurotoxin E does not reduce the duration of paralysis caused by botulinum neurotoxin A in rat EDL muscle. Botulinum J 1:442–456

    Google Scholar 

  13. Adler M, Deshpande SS, Apland JP, Murray B, Borrell A (2012) Reversal of BoNT/A-mediated inhibition of muscle paralysis by 3,4-diaminopyridine and roscovitine in mouse phrenic nerve-hemidiaphragm preparations. Neurochem Int 61:866–873

    CAS  PubMed  Google Scholar 

  14. Agarwal R, Binz T, Swaminathan S (2005) Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design. BioChemistry 44:11758–11765

    CAS  PubMed  Google Scholar 

  15. Ahmed SA, Smith LA (2000) Light chain of botulinum neurotoxin expressed as inclusion body from a synthetic gene is catalytically and functionally active. J Protein Chem 19:475–487

    CAS  PubMed  Google Scholar 

  16. Aisen ML, Sevilla D, Gibson G, Kutt H, Blau A, Edelstein L, Hatch J, Blass J (1995) 3,4-Diaminopyridine as a treatment for amyotrophic lateral sclerosis. J Neurol Sci 129:21–24

    CAS  PubMed  Google Scholar 

  17. Aldoss IT, Tashi T, Ganti AK (2009) Seliciclib in malignancies. Expert Opin Investig Drugs 18:1957–1965

    CAS  PubMed  Google Scholar 

  18. Al-Saleem FH, Ancharski DM, Joshi SG, Elias M, Singh A, Nasser Z, Simpson LL (2012) Analysis of the mechanisms that underlie absorption of botulinum toxin by the inhalation route. Infect Immun 80:4133–4142

    CAS  PubMed Central  PubMed  Google Scholar 

  19. Ambache N (1951) A further survey of the action of Clostridium botulinum toxin upon different type of autonomic nerve fibre. J Physiol (Lond) 113:1–17

    CAS  Google Scholar 

  20. Amersdorfer P, Wong C, Chen S, Smith T, Deshpande S, Sheridan R, Finnern R, Marks JD (1997) Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect Immun 65:3743–3752

    CAS  PubMed Central  PubMed  Google Scholar 

  21. Anderson PD (2012) Bioterrorism: toxins as weapons. J Pharm Pract 25:121–129

    PubMed  Google Scholar 

  22. Aoki KR (2002) Physiology and pharmacology of therapeutic botulinum neurotoxins. Curr Probl Dermatol 30:107–116

    CAS  PubMed  Google Scholar 

  23. Aoki KR, Smith LA, Atassi MZ (2010) Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition. Crit Rev Immunol 30:167–187

    CAS  PubMed  Google Scholar 

  24. Arndt JW, Chai Q, Christian T, Stevens RC (2006) Structure of botulinum neurotoxin type D light chain at 1.65 Å resolution: repercussions for VAMP-2 substrate specificity. BioChemistry 45:3255–3262

    CAS  PubMed  Google Scholar 

  25. Arnon SS (1995) Botulism as an intestinal toxaemia. In: Blaser MJ, Smith PD, Ravdin JI, Greenberg HB, Guerrant RL (eds) Infections of the gastrointestinal tract. Raven Press, New York, pp 257–271

    Google Scholar 

  26. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O’Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:1059–1070

    CAS  PubMed  Google Scholar 

  27. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL (2006) Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 354:462–471

    CAS  PubMed  Google Scholar 

  28. Atassi MZ, Dolimbek BZ (2004) Mapping of the antibody-binding regions on the HN-domain (residues 449–859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the antigenic regions of the H-chain of botulinum neurotoxin A. Protein J 23:39–52

    CAS  PubMed  Google Scholar 

  29. Atlas RM (1998) The medical threat of biological weapons. Crit Rev Microbiol 24:157–168

    CAS  PubMed  Google Scholar 

  30. Bakry N, Kamata Y, Simpson LL (1991) Lectins from Triticum vulgaris and Limax flavus are universal antagonists of botulinum neurotoxin and tetanus toxin. J Pharmacol Exp Ther 258:830–836

    CAS  PubMed  Google Scholar 

  31. Baldwin MR, Tepp WH, Przedpelski A, Pier CL, Bradshaw M, Johnson EA, Barbieri JT (2008) Subunit vaccine against the seven serotypes of botulism. Infect Immun 76:1314–1318

    CAS  PubMed Central  PubMed  Google Scholar 

  32. Barash JR, Arnon SS (2013) A novel strain of clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis [epub ahead of print] PMID 24106296

    Google Scholar 

  33. Bavari S, Pless DD, Torres ER, Lebeda FJ, Olson MA (1998) Identifying the principal protective antigenic determinant of type A botulinum neurotoxin. Vaccine 16:1850–1856

    CAS  PubMed  Google Scholar 

  34. Bhutani M, Ralph E, Sharpe MD (2005) Acute paralysis following “a bad potato”: a case of botulism. Can J Anaesth 52:433–4336

    PubMed  Google Scholar 

  35. Black RE, Gunn RA (1980) Hypersensitivity reactions associated with botulinal antitoxin. Am J Med 69:567–570

    CAS  PubMed  Google Scholar 

  36. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, Sudhof TC, Niemann H, Jahn R (1993) Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 365:160–163

    CAS  PubMed  Google Scholar 

  37. Bogdan J, Spinelli B, Gottdiener P, Harris R, McInnis J, Hollomon E, Ranallo R (2013) 10 Years of developing botulinum neurotoxin (BoNT) therapeutics at NIAID. 50th Annual Interagency Botulinum Research Coordinating Committee Meeting, Annapolis, MD

    Google Scholar 

  38. Boldt GE, Eubanks LM, Janda KD (2006a) Identification of a botulinum neurotoxin A protease inhibitor displaying efficacy in a cellular model. Chem Commun 29:3063–3065

    Google Scholar 

  39. Boldt GE, Kennedy JP, Janda KD (2006b) Identification of a potent botulinum neurotoxin A protease inhibitor using in situ lead identification chemistry. Org Lett 8:1729–1732

    CAS  Google Scholar 

  40. Boles J, West M, Montgomery V, Tammariello R, Pitt ML, Gibbs P, Smith L, LeClair RD (2006) Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey. Toxicon 47:877–884

    CAS  PubMed  Google Scholar 

  41. Brashear A (2010) Botulinum toxin type A: exploring new indications. Drugs Today (Barc) 46:671–682

    CAS  Google Scholar 

  42. Breidenbach MA, Brunger AT (2004) Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432:925–929

    CAS  PubMed  Google Scholar 

  43. Brin MF (2009) Basic and clinical aspects of BOTOX. Toxicon 54:676–682

    CAS  PubMed  Google Scholar 

  44. Brooks VB (1956) An intracellular study of the action of repetitive nerve volleys and of botulinum toxin on miniature end-plate potentials. J Physiol (Lond) 134:264–277

    CAS  Google Scholar 

  45. Buraei Z, Schofield G, Elmslie KS (2007) Distinct kinetic changes in neurotransmitter release after SNARE protein cleavage. Neuropharmacology 52:883–894

    CAS  PubMed  Google Scholar 

  46. Burgen ASV, Dickens F, Zatman LJ (1949) The action of botulinum toxin on the neuromuscular junction. J Physiol (Lond) 109:10–24

    CAS  Google Scholar 

  47. Burnett JC, Schmidt JJ, Stafford RG, Panchal RG, Nguyen TL, Hermone AR, Vennerstrom JL, McGrath CF, Lane DJ, Sausville EA, Zaharevitz DW, Gussio R, Bavari S (2003) Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochem Biophys Res Commun 310:84–93

    CAS  PubMed  Google Scholar 

  48. Burnett JC, Schmidt JJ, McGrath CF, Nguyen TL, Hermone AR, Panchal RG, Vennerstrom JL, Kodukula K, Zaharevitz DW, Gussio R, Bavari S (2005) Conformational sampling of the botulinum neurotoxin serotype A light chain: implications for inhibitor binding. Bioorg Med Chem 13:333–341

    CAS  PubMed  Google Scholar 

  49. Burnett JC, Ruthel G, Stegmann CM, Panchal RG, Nguyen TL, Hermone AR, Stafford RG, Lane DJ, Kenny TA, McGrath CF, Wipf P, Stahl AM, Schmidt JJ, Gussio R, Brunger AT, Bavari S (2007a) Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. J Biol Chem 282:5004–5501

    CAS  Google Scholar 

  50. Burnett JC, Opsenica D, Sriraghavan K, Panchal RG, Ruthel G, Hermone AR, Nguyen TL, Kenny TA, Lane DJ, McGrath CF, Schmidt JJ, Vennerstrom JL, Gussio R, Solaja BA, Bavari S (2007b) A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype A metalloprotease. J Med Chem 50:2127–2136

    CAS  Google Scholar 

  51. Burnett JC, Wang C, Nuss JE, Nguyen TL, Hermone AR, Schmidt JJ, Gussio R, Wipf P, Bavari S (2009) Pharmacophore-guided lead optimization: the rational design of a non-zinc coordinating, sub-micromolar inhibitor of the botulinum neurotoxin serotype A metalloprotease. Bioorg Med Chem Lett 19:5811–5813

    CAS  PubMed  Google Scholar 

  52. Byrne MP, Smith TJ, Montgomery VA, Smith LA (1998) Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun 66:4817–4822

    CAS  PubMed Central  PubMed  Google Scholar 

  53. Byrne MP, Titball RW, Holley J, Smith LA (2000) Fermentation, purification and efficacy of a recombinant vaccine candidate against botulinum neurotoxin serotype F from Pichia pastoris. Protein Expr Purif 18:327–337

    CAS  PubMed  Google Scholar 

  54. Čapková K, Hixon MS, McAllister LA, Janda KD (2008) Toward the discovery of potent inhibitors of botulinum neurotoxin A: development of a robust LC MS based assay operational from low to subnanomolar enzyme concentrations. Chem Commun (Camb) 14(30):3525–3527

    Google Scholar 

  55. Carruthers J, Carruthers A (2009) Botulinum toxin in facial rejuvenation: an update. Dermatol Clin 27:417–425

    CAS  PubMed  Google Scholar 

  56. CDC (2010) Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR 59:299

    Google Scholar 

  57. CDC (2011) Notice of CDC’s discontinuation of investigational pentavalent (ABCDE) botulinum toxoids vaccine for workers at risk of occupational exposure to botulinum toxins. MMWR 60:1454–1455

    Google Scholar 

  58. Chai Q, Arndt JW, Dong M, Tepp WH, Johnson EA, Chapman ER, Stevens RC (2006) Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 444:1090–1100

    Google Scholar 

  59. Charles PD (2004) Botulinum neurotoxin serotype A: a clinical update on non-cosmetic uses. Am J Health Syst Pharm 61:S11–S23

    CAS  PubMed  Google Scholar 

  60. Chen S, Barbieri JT (2006) Unique substrate recognition by botulinum neurotoxins serotypes A and E. J Biol Chem 281:10906–10911

    CAS  PubMed  Google Scholar 

  61. Cheng LW, Stanker LH, Henderson IITD, Lou J, Marks JD (2009) Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun 77:4305–4313

    CAS  PubMed Central  PubMed  Google Scholar 

  62. Cherington M (1998) Clinical spectrum of botulism. Muscle Nerve 21:701–710

    CAS  PubMed  Google Scholar 

  63. Cherington M, Ryan DW (1968) Botulism and guanidine. N Engl J Med 278:931–933

    CAS  PubMed  Google Scholar 

  64. Cherington M, Schultz D (1977) Effect of guanidine, germine and steroids in a case of botulism. Clin Toxicol 11:19–25

    CAS  PubMed  Google Scholar 

  65. Chertow DS, Tan ET, Maslanka S, Schulte J, Bresnitz EA, Weisman RS, Bernstein J, Marcus SM, Kumar S, Malecki J, Sobel J, Braden CR (2006) Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA 296:2476–2479

    CAS  PubMed  Google Scholar 

  66. Clapp B, Golden S, Maddaloni M, Staats HF, Pascual DW (2010) Adenovirus F protein as a delivery vehicle for botulinum B. BMC Immunol 11:36

    PubMed Central  PubMed  Google Scholar 

  67. Clayton MA, Clayton JM, Brown DR, Middlebrook JL (1995) Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun 63:2738–2742

    CAS  PubMed Central  PubMed  Google Scholar 

  68. Cohen FL, Hardin SB, Nehring W, Keough MA, Laurenti S, McNabb J, Platis C, Weber C (1988) Physical and psychosocial health status 3 years after catastrophic illness-botulism. Issues Ment Health Nurs 9:387–398

    CAS  PubMed  Google Scholar 

  69. Critchley EM, Hayes PJ, Isaacs PE (1989) Outbreak of botulism in north west England and Wales, June 1989. Lancet 2:849–853

    CAS  PubMed  Google Scholar 

  70. Cull-Candy SG, Lundh H, Thesleff S (1976) Effects of botulinum toxin on neuromuscular transmission in the rat. J Physiol (Lond) 260:177–203

    CAS  Google Scholar 

  71. Davis LE, Johnson JK, Bicknell JM, Levy H, McEvoy KM (1992) Human type A botulism and treatment with 3,4-diaminopyridine. Electromyogr Clin Neurophysiol 32:379–383

    CAS  PubMed  Google Scholar 

  72. Delgado-Martínez I, Nehring RB, Sørensen JB (2007) Differential abilities of SNAP-25 homologs to support neuronal function. J Neurosci 27:9380–9391

    PubMed  Google Scholar 

  73. Dembek ZF, Smith LA, Rusnak JM (2007) Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Med Public Health Prep 1:122–134

    PubMed  Google Scholar 

  74. Deshpande SS, Sheridan RE, Adler M (1995) A study of zinc-dependent metalloendopeptidase inhibitors as pharmacological antagonists in botulinum neurotoxin poisoning. Toxicon 33:551–557

    CAS  PubMed  Google Scholar 

  75. Deshpande SS, Sheridan RE, Adler M (1997) Efficacy of certain quinolines as pharmacological antagonists in botulinum neurotoxin poisoning. Toxicon 35:433–445

    CAS  PubMed  Google Scholar 

  76. DeStefino NR, Pilato AA, Dittrich M, Cherry SV, Cho S, Stiles JR, Meriney SD (2010) (R)-roscovitine prolongs the mean open time of unitary N-type calcium channel currents. Neuroscience 167:838–849

    CAS  PubMed Central  PubMed  Google Scholar 

  77. Devers KG, Nine JS (2010) Autopsy findings in botulinum toxin poisoning. J Forensic Sci 55:1649–1651

    PubMed  Google Scholar 

  78. Dickerson TJ, Janda KD (2006) The use of small molecules to investigate molecular mechanisms and therapeutic targets for treatment of botulinum neurotoxin A intoxication. ACS Chem Biol 1:359–369

    CAS  PubMed  Google Scholar 

  79. Dong M, Richards DA, Goodnough MC, Tepp WH, Johnson EA, Chapman ER (2003) Synaptotagmins I and II mediate entry of botulinum neurotoxin into cells. J Cell Biol 162:1293–1303

    CAS  PubMed Central  PubMed  Google Scholar 

  80. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312:592–596

    CAS  PubMed  Google Scholar 

  81. Dong J, Thompson AA, Fan Y, Lou J, Conrad F, Ho M, Pires-Alves M, Wilson BA, Stevens RC, Marks JD (2010) A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. Mol Biol 397:1106–1118

    CAS  Google Scholar 

  82. Dressler D (2010) Comparing Botox and Xeomin for axillary hyperhidrosis. J Neural Transm 117:317–319

    PubMed  Google Scholar 

  83. Dressler D, Eleopra R (2006) Clinical use of non-A botulinum toxins: botulinum toxin type B. Neurotox Res 9:121–125

    CAS  PubMed  Google Scholar 

  84. Dressler D, Müchau A, Bhatia KP, Quinn NP, Bigalke H (2002) Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses? Eur Neurol 47:118–121

    CAS  PubMed  Google Scholar 

  85. Dutton JJ, Fowler AM (2007) Botulinum toxin in ophthalmology. Surv Ophthalmol 52:13–31

    PubMed  Google Scholar 

  86. Edmunds CW, KeiperGF Jr (1924) Further studies on the action of botulinus toxin. JAMA 83:495–501

    CAS  Google Scholar 

  87. Eisel U, Jarausch W, Goretzki K, Henschen A, Engels J, Weller U, Hudel M, Habermann E, Niemann H (1986) Tetanus toxin: primary structure, expression in E. coli, and homology with botulinum toxins. EMBO J 5:2495–2502

    CAS  PubMed Central  PubMed  Google Scholar 

  88. Emanuel P, O’Brien T, Burans J, DasGupta BR, Valdes JJ, Eldefrawi M (1996) Directing antigen specificity towards botulinum neurotoxin with combinatorial phage display libraries. J Immunol Methods 193:189–197

    CAS  PubMed  Google Scholar 

  89. Eubanks LM, Hixon MS, Jin W, Hong S, Clancy CM, Tepp WH, Baldwin MR, Malizio CJ, Goodnough MC, Barbieri JT, Johnson EA, Boger DL, Dickerson TJ, Janda K (2007) An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci U S A 104:2602–2607

    CAS  PubMed Central  PubMed  Google Scholar 

  90. Eubanks LM, Silhár P, Salzameda NT, Zakhari JS, Xiaochuan F, Barbieri JT, Shoemaker CB, Hixon MS, Janda KD (2010) Identification of a natural product antagonist against the botulinum neurotoxin light chain protease. ACS Med Chem Lett 1:268–272

    CAS  PubMed Central  PubMed  Google Scholar 

  91. Fagan RP, Neil KP, Sasich R, Luquez C, Asaad H, Maslanka S, Khalil W (2011) Initial recovery and rebound of type F intestinal colonization botulism after administration of investigational heptavalent botulinum antitoxin. Clin Infect Dis 53:e125–128

    CAS  PubMed  Google Scholar 

  92. Fairweather NF, Lyness VA, Maskell DJ (1987) Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli. Infect Immun 55:2541–2545

    CAS  PubMed Central  PubMed  Google Scholar 

  93. Fernandez-Salas E, Steward LE, Ho H, Garay PE, Sun SW, Gilmore MA, Ordas JV, Wang J, Francis J, Aoki KR (2004) Plasma membrane localization signals in the light chain of botulinum neurotoxin. Proc Natl Acad Sci U S A 101:3208–3213

    CAS  PubMed Central  PubMed  Google Scholar 

  94. Fiock MA, Cardella MA, Gearinger NF (1963) Studies on immunity to toxins of Clostridium botulinum. IX. Immunologic response of man to purified petavalent ABCDE botulinum toxoid. J Immunol 90:697–702

    CAS  PubMed  Google Scholar 

  95. Fischer A, Montal M (2006) Characterization of clostridial botulinum neurotoxin channels in neuroblastoma cells. Neurotox Res 9:93–100

    CAS  Google Scholar 

  96. Fischer A, Nakai Y, Eubanks LM, Clancy CM, Tepp WH, Pellett S, Dickerson TJ, Johnson EA, Janda KD, Montal M (2009) Bimodal modulation of the botulinum neurotoxin protein-conducting channel. Proc Natl Acad Sci U S A 106:1330–1335

    CAS  PubMed Central  PubMed  Google Scholar 

  97. Foran PG, Mohammed N, Lisk GO, Nagwaney S, Lawrence GW, Johnson E, Smith L, Aoki KR, Dolly JO (2003) Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem 278:1363–1371

    CAS  PubMed  Google Scholar 

  98. Foster KA (2005) A new wrinkle on pain relief: re-engineering clostridial neurotoxins for analgesics. Drug Discov Today 10:563–569

    CAS  PubMed  Google Scholar 

  99. Foster KA, Adams EJ, Durose L, Cruttwell CJ, Marks E, Shone CC, Chaddock JA, Cox CL, Heaton C, Sutton JM, Wayne J, Alexander FC, Rogers DF (2006) Re-engineering the target specificity of clostridial neurotoxins- a route to novel therapeutics. Neurotox Res 9:101–107

    CAS  PubMed  Google Scholar 

  100. Franz DR, Pitt LM, Clayton MA, Hanes MA, Rose KJ (1993) Efficacy of prophylactic and therapeutic administration of antitoxin for inhalation botulism. In: DasGupta BR (ed) Botulinum and tetanus neurotoxins and biomedical aspects. Plenum Press, New York, pp 473–476

    Google Scholar 

  101. Franz DR, Jahrling PB, Friedlander AM, McClain DJ, Hoover DL, Bryne WR, Pavlin JA, Christopher GW, Eitzen EM Jr (1997) Clinical recognition and management of patients exposed to biological warfare agents. JAMA 278:399–411

    CAS  PubMed  Google Scholar 

  102. Fujihashi K, Staats HF, Kozaki S, Pascual DW (2007) Mucosal vaccine development for botulinum intoxication. Expert Rev Vaccines 6:34–45

    Google Scholar 

  103. Gelzleichter TR, Myers MA, Menton RG, Niemuth NA, Matthews MC, Langford MJ (1999) Protection against botulinum toxins provided by passive immunization with botulinum human immune globulin: evaluation using an inhalation model. J Appl Toxicol 19:S35–S38

    CAS  PubMed  Google Scholar 

  104. Gill DM (1982) Bacterial toxins: a table of lethal amounts. Microbiol Rev 46:86–94

    CAS  PubMed Central  PubMed  Google Scholar 

  105. Giménez DF, Ciccarelli AS (1970) Another type of Clostridium botulinum. Zentralbl Bakteriol Orig 215:221–224

    PubMed  Google Scholar 

  106. Goldman ER, Anderson GP, Bernstein RW, Swain MD (2010) Amplification of immunoassays using phage-displayed single domain antibodies. J Immunol Methods 352:182–185

    CAS  PubMed  Google Scholar 

  107. Gomez S, Queiroz LS (1982) The effects of black widow spider venom on the innervation of muscles paralysed by botulinum toxin. Q J Exp Physiol 67:495–506

    Google Scholar 

  108. Goodnough MC, Oyler G, Fishman PS, Johnson EA, Neale EA, Keller JE, Tepp WH, Clark M, Hartz S, Adler M (2002) Development of a delivery vehicle for intracellular transport of botulinum neurotoxin antagonists. FEBS Lett 513:163–168

    CAS  PubMed  Google Scholar 

  109. Gu S, Rumpel S, Zhou J, Strotmeier J, Bigalke H, Perry K, Shoemaker CB, Rummel A, Jin R (2012) Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science 335:977–981

    CAS  PubMed Central  PubMed  Google Scholar 

  110. Guendel I, Agbottah ET, Kehn-Hall K, Kashanchi F (2010) Inhibition of human immunodeficiency virus type-1 by cdk inhibitors. Aids Res Ther 7:1–14

    Google Scholar 

  111. Gul N, Smith LA, Ahmed SA (2010) Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form. PloS One 5(9):e12872

    PubMed Central  PubMed  Google Scholar 

  112. Guyton AC, MacDonald MA (1947) Physiology of botulinum toxin. Arch Neurol Psych 57:578-592

    CAS  Google Scholar 

  113. Hart MK, Saviolakis GA, Welkos SL, House RV (2012) Advanced development of the rF1V and rBV A/B vaccines. Adv Prev Med 2012:731604

    PubMed Central  PubMed  Google Scholar 

  114. Hatheway CL (1990) Toxigenic clostridia. Clin Microbiol Rev 3:66–98

    CAS  PubMed Central  PubMed  Google Scholar 

  115. Hatheway CL, Snyder JD, Seals JE, Edell TA, Lewis GE Jr (1984) Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. J Infect Dis 150:407–412

    CAS  PubMed  Google Scholar 

  116. Henderson DA (1999) The looming threat of bioterrorism. Science 283:1279–1282

    CAS  PubMed  Google Scholar 

  117. Hermone AR, Burnett JC, Nuss JE, Tressler LE, Nguyen TL, Solaja BA, Vennerstrom JL, Schmidt JJ, Wipf P, Bavari S, Gussio R (2008) Three-dimensional database mining identifies a unique chemotype that unites structurally diverse botulinum neurotoxin serotype A inhibitors in a three-zone pharmacophore. ChemMedChem 3:1905–1912

    CAS  PubMed  Google Scholar 

  118. Hewlett RT (1929) Bacillus botulinus. A system of bacteriology in relation to medicine, vol III. Med Research Council, London, pp 373–406

    Google Scholar 

  119. Hibbs RG, Weber JT, Corwin A, Allos BM, Abd ERehimMS, El Sharkawy S, Sarn JE, McKee KT Jr (1996) Experience with the use of an investigational F(ab’)2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Clin Infect Dis 23:337–340

    CAS  PubMed  Google Scholar 

  120. Hill SE, Iqbal R, Cadiz CL, Le J (2013) Foodborn botulism treated with heptavalent botulism antitoxin. Ann Pharmacother 47:e12

    PubMed  Google Scholar 

  121. Ho CY, Strobel E, Ralbovsky J, Galemmo RA Jr (2005) Improved solution-and solid-phase preparation of hydroxamic acids from esters. J Org Chem 70:4873–4875

    CAS  PubMed  Google Scholar 

  122. Howe JR, Ritchie JM (1991) On the active form of 4-aminopyridine: block of K currents in rabbit Schwann cells. J Physiol (Lond) 433:183–205

    CAS  Google Scholar 

  123. Jin R, Rummel A, Binz T, Brunger AT (2006) Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 444:1092–1095

    CAS  PubMed  Google Scholar 

  124. Johnson SK, Zhang W, Smith LA, Hywood-Potter KJ, Todd Swanson S, Schlegel VL, Meagher MM (2003) Scale-up of the fermentation and purification of the recombinant heavy chain fragment C of botulinum neurotoxin serotype F, expressed in Pichia pastoris. Protein Expr Purif 32:1–9

    CAS  PubMed  Google Scholar 

  125. Jurasinski CV, Leith E, Dang Do AN, Schengrund CL (2001) Correlation of cleavage of SNAP-25 with muscle function in a rat model of botulinum neurotoxin type A induced paralysis. Toxicon 39:1309–1315

    CAS  PubMed  Google Scholar 

  126. Kao I, Drachman DB, Price DL (1976) Botulinum toxin: mechanism of presynaptic blockade. Science 193:1256–1258

    CAS  PubMed  Google Scholar 

  127. Keller JE (2008) Characterization of new formalin-detoxified botulinum neurotoxin toxoids. Clin Vaccine Immunol 15:1374–1379

    CAS  PubMed Central  PubMed  Google Scholar 

  128. Keller JE, Neale EA (2001) The role of the synaptic protein SNAP-25 in the potency of botulinum neurotoxin A. J Biol Chem 276:13476–13482

    CAS  PubMed  Google Scholar 

  129. Keller JE, Neale EA, Oyler G, Adler M (1999) Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett 456:137–142

    CAS  PubMed  Google Scholar 

  130. Kimura K, Fujii N, Tsuzuki K, Murakami T, Indoh T, Yokosawa N, Oguma K (1991) Cloning of the structural gene for Clostridium botulinum type C1 toxin and whole nucleotide sequence of its light chain component. Appl Environ Microbiol 57:1168–1172

    CAS  PubMed Central  PubMed  Google Scholar 

  131. Knockaert M, Greengard P, Meijer L (2002) Pharmacologic inhibitors of cycline dependent kinase. Trends Pharmacol Sci 23:417–425

    CAS  PubMed  Google Scholar 

  132. Kobayashi H, Fujisawa K, Saito Y, Kamijo M, Oshima S, Kubo M, Eto Y, Monma C, Kitamura M (2003) A botulism case of a 12-year old girl caused by intestinal colonization of Clostridium botulinum type Ab. Jpn J Infect Dis 56:73–74

    PubMed  Google Scholar 

  133. Kobayashi R, Kohda T, Kataoka K, Ihara H, Kozaki S, Pascual DW, Staats HF, Kiyono H, McGhee JR, Fujihashi K (2005) A novel neurotoxoid vaccine prevents mucosal botulism. J Immunol 174:2190–2195

    CAS  PubMed  Google Scholar 

  134. Kohda T, Ihara H, Seto Y, Tsutsuki H (2007) Differential contribution of the residues in C-terminal half of the heavy chain of botulinum neurotoxin type B to its binding to the ganglioside GT1b and the synaptotagmin 2/GT1b complex. Microb Pathog 42:72–79

    CAS  PubMed  Google Scholar 

  135. Koriazova LK, Montal M (2003) Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol 10:13–18

    CAS  PubMed  Google Scholar 

  136. Kumaran D, Rawat R, Ludivico ML, Ahmed SA, Swaminathan S (2008) Structure-and substrate-based inhibitor design for Clostridium botulinum neurotoxin serotype A. J Biol Chem 283:18883–18891

    CAS  PubMed  Google Scholar 

  137. Kuo CL, Oyler GA, Shoemaker CB (2011) Accelerated neuronal cell recovery from botulinum neurotoxin intoxication by targeted ubiquitination. PloS One 6(5):e20352

    CAS  PubMed Central  PubMed  Google Scholar 

  138. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5:898–902

    CAS  PubMed  Google Scholar 

  139. Lebeda FJ, Adler M (2010) Hydrodynamic models for the diffusivity of type A botulinum neurotoxin. Botulinum J 1:393–406

    Google Scholar 

  140. Lebeda FJ, Cer RZ, Stephens RM, Mudunuri U (2010) Temporal characteristics of botulinum neurotoxin therapy. Expert Rev Neurother 10:93–103

    CAS  PubMed Central  PubMed  Google Scholar 

  141. Lee JS, Pushko P, Parker MD, Dertzbaugh MT, Smith LA, Smith JF (2001) Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. Infect Immun 69:5709–5715

    CAS  PubMed Central  PubMed  Google Scholar 

  142. Le Tourneau C, Faivre S, Laurence V, Delbaldo C, Vera K, Girre V, Chiao J, Armour S, Frame S, Green SR, Gianella-Borradori A, Diéras V, Raymond E (2010) Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer 46:3243–3250

    CAS  PubMed  Google Scholar 

  143. Li MF, Shi YL (2006) Toosendanin interferes with pore formation of botulinum toxin type A in PC12 cell membrane. Acta Pharmacol Sin 27:66–70

    PubMed  Google Scholar 

  144. Li B, Peet NP, Butler MM, Burnett JC, Moir DT, Bowlin TL (2010) Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication. Molecules 16:202–220

    PubMed  Google Scholar 

  145. Lin MJ, Lin-Shiau SY (1997) Multiple types of Ca2 + channels in mouse motor nerve terminals. Eur J Neurosci 9:817–823

    CAS  PubMed  Google Scholar 

  146. Lindström M, Korkeala H (2006) Laboratory diagnostics of botulism. Clin Microbiol Rev 19:298–314

    PubMed Central  PubMed  Google Scholar 

  147. Liu Z, Zhang C, Li Y, Song C, Sun Y, Wei Y, Xu Z, Yang A, Xu Z, Yang K, Jin B (2012) High sensitivity ELISA for detection of botulinum neurotoxin serotype F. Hybridoma (Larchmt) 31:233–239

    CAS  Google Scholar 

  148. Lundh H, Leander S, Thesleff S (1977) Antagonism of the paralysis produced by botulinum toxin in the rat. The effects of tetraethylammonium, guanidine and 4-aminopyridine. J Neurol Sci 32:29–43

    CAS  PubMed  Google Scholar 

  149. Maddaloni M, Staats HF, Mierzejewska D, Hoyt T, Robinson A, Callis G, Kozaki S, Kiyono H, McGhee JR, Fujihashi K, Pascual DW (2006) Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin A. J Immunol 177:5524–5532

    CAS  PubMed  Google Scholar 

  150. Mann J (1983) Prolonged recovery from type A botulism. N Engl J Med 309:1522–1523

    CAS  PubMed  Google Scholar 

  151. Marcus SM (2009) Reflections on the care of a patient severely poisoned by ‘rogue’ botulinum toxin and rendered paralysed for a protracted hospital stay. The Botulinum J 1:318–339

    Google Scholar 

  152. Marks JD (2004) Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. Movement Disorders Supplement 8:S101–S108

    Google Scholar 

  153. Matarasso A, Shafer D (2009) Botulinum neurotoxin type A-ABO (Dysport): clinical indications and practice guide. Aesthet Surg J 29:S72–S79

    PubMed  Google Scholar 

  154. Mayers CN, Holley JL, Brooks T (2001) Antitoxin therapy for botulinum intoxication. Rev Med Microbiol 12:29–37

    Google Scholar 

  155. Mayorov AV, Willis B, Di Mola A, Adler D, Borgia J, Jackson O, Wang J, Luo Y, Tang L, Knapp RJ, Natarajan C, Goodnough MC33, Zilberberg N, Simpson LL, Janda KD (2010) Symptomatic relief of botulinum neurotoxin/A intoxication with aminopyridines: a new twist on an old molecule. ACS Chem Biol 5:1183–1191

    CAS  PubMed Central  PubMed  Google Scholar 

  156. McClue SJ, Stuart I (2008) Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo. Drug Metab Dispos 36:561–570

    CAS  PubMed  Google Scholar 

  157. Meng J, Ovsepian SV, Wang J, Pickering M, Sasse A, Aoki KR, Lawrence GW, Dolly JO (2009) Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci 29:4981–4992

    CAS  PubMed  Google Scholar 

  158. Merino I, Thompson JD, Millard CB, Schmidt JJ, Pang YP (2006) Bis-imidazoles as molecular probes for peripheral sites of the zinc endopeptidase of botulinum neurotoxin serotype A. Bioorg Med Chem 14:3583–3591

    CAS  PubMed  Google Scholar 

  159. Merz B, Bigalke H, Stoll G, Naumann M (2003) Botulism type B presenting as pure autonomic dysfunction. Clin Auton Res 13:337–338

    CAS  PubMed  Google Scholar 

  160. Mesngon M, McNutt P (2011) Alpha-latrotoxin rescues SNAP-25 from BoNT/A-mediated proteolysis in embryonic stem cell-derived neurons. Toxins 3:489–503

    CAS  PubMed Central  PubMed  Google Scholar 

  161. Meyer K, Ng H, Parman T, D’Andrea A, Harrison T, Green C, Ma J, Cao L, Shimizu B, Der K, Mirsalis J (2011) Nonclinical safety evaluation of XOMA 3AB, a novel triple monoclonal antibody drug product targeting botulinum toxin type A, in Sprague-Dawley rats. Poster presented at the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Meeting, January 10–12, 2011, Washington, DC

    Google Scholar 

  162. Middlebrook JL, Franz DR (1997) Botulinum toxins. In: Zajtchuk R, Bellamy RF (eds) Textbook of military medicine: medical aspects of chemical and biological warfare, part I. Borden Institute, Washington, DC, pp 643–654

    Google Scholar 

  163. Moe ST, Thompson AB, Smith GM, Fredenburg RA, Stein RL, Jacobson AR (2009) Botulinum neurotoxin serotype A inhibitors: small-molecule mercaptoacetamide analogs. Bioorg Med Chem 17:3072–3079

    CAS  PubMed Central  PubMed  Google Scholar 

  164. Molgó J, Lundh H, Thesleff S (1980) Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur J Pharmacol 61:25–34

    PubMed  Google Scholar 

  165. Molgó J, Lemeignan M, Thesleff S (1987) Aminoglycosides and 3,4-diaminopyridine on neuromuscular block cause by botulinum type A toxin. Muscle Nerve 10:464–470

    PubMed  Google Scholar 

  166. Moller V, Scheibel I (1960) Preliminary report on the isolation of an apparently new type of Clostridium botulinum. Acta Pathol Microbiol Scand 48:80

    CAS  PubMed  Google Scholar 

  167. Montecucco C (1986) How do tetanus and botulinum toxins bind to neuronal membranes? Trends Biochem Sci 11:314–317

    CAS  Google Scholar 

  168. Montecucco C, Schiavo G (1993) Tetanus and botulism neurotoxins: a new group of zinc proteases. Trends Biochem Sci 18:324–327

    CAS  PubMed  Google Scholar 

  169. Montecucco C, Papini E, Schiavo G (1994) Bacterial protein toxins penetrate cells via a four-step mechanism. FEBS Lett 346:92–98

    CAS  PubMed  Google Scholar 

  170. Muñoz-Caro C, Niño A (2002) The nature of the receptor site for the reversible K + channel blocking by aminopyridines. Biophys Chem 96:1–14

    PubMed  Google Scholar 

  171. Mustafa W, Al-Saleem FH, Nasser Z, Olson RM, Mattis JA, Simpson LL, Schnell MJ (2011) Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge. Vaccine 29:4638–4645

    CAS  PubMed Central  PubMed  Google Scholar 

  172. Nakamura Y, Takahashi T (2007) Developmental changes in potassium currents at the rat calyx of held presynaptic terminal. J Physiol (Lond) 581:1101–1112

    CAS  Google Scholar 

  173. Nishiki T, Tokuyama Y, Kamata Y, Nemoto Y, Yoshida A, Sato K, Sekiguchi M, Takahashi M, Kozaki S (1996) The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1. FEBS Lett 378:253–257

    CAS  PubMed  Google Scholar 

  174. Nowakowski A, Wang C, Powers DB, Armersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD (2002) Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A 99:11346–11135

    CAS  PubMed Central  PubMed  Google Scholar 

  175. Nuss JE, Dong Y, Wanner LM, Ruthel G, Wipf P, Gussio R, Vennerstrom JL, Bavari S, Burnett JC (2010) Pharmacophore refinement guides the rational design of nanomolar-range inhibitors of the botulinum neurotoxin serotype A metalloprotease. ACS Med Chem Lett 14:301–305

    Google Scholar 

  176. Oost T, Sukonpan C, Brewer M, Goodnough M, Tepp W, Johnson EA, Rich DH (2003) Design and synthesis of substrate-based inhibitors of botulinum neurotoxin type B metalloprotease. Biopolymers 71:602–619

    CAS  PubMed  Google Scholar 

  177. Opsenica I, Burnett JC, Gussio R, Opsenica D, Todorović N, Lanteri CA, Sciotti RJ, Gettayacamin M, Basilico N, Taramelli D, Nuss JE, Wanner L, Panchal RG, Solaja BA, Bavari S (2011) A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus. J Med Chem 54:1157–1169

    CAS  PubMed Central  PubMed  Google Scholar 

  178. O’Sullivan GA, Mohammed N, Foran PG, Lawrence GW, Dolly JO (1999) Rescue of exocytosis in botulinum toxin A-poisoned chromaffin cells by expression of cleavage resistant SNAP-25. Identification of the minimal essential C-terminal residues. J Biol Chem 274:36897–36904

    PubMed  Google Scholar 

  179. Pang YP (2001) Successful molecular dynamics simulation of two zinc complexes bridged by a hydroxide in hosphotriesterase using the cationic dummy atom method. Proteins 45:183–189

    CAS  PubMed  Google Scholar 

  180. Pang YP, Vummenthala A, Mishra RK, Park JG, Wang S, Davis J, Millard CB, Schmidt JJ (2009) Potent new small-molecule inhibitor of botulinum neurotoxin serotype A endopeptidases developed by synthesis-based computer-aided molecular design. PloS One 4(11):e7730

    PubMed Central  PubMed  Google Scholar 

  181. Pang YP, Davis J, Wang S, Park JG, Nambiar MP, Schmidt JJ, Millard CB (2010) Small molecules showing significant protection of mice against botulinum neurotoxin serotype A. PloS One 5(4):e10129

    PubMed Central  PubMed  Google Scholar 

  182. Pantano S, Montecucco C (2013) The blockade of the neurotransmitter release apparatus by botulinum neurotoxins. Cell Mol Life Sci PMID: 23749048 (Epub ahead of print)

    Google Scholar 

  183. Park J-B, Simpson LL (2003) Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component. Infect Immun 71:1147–1154

    CAS  PubMed Central  PubMed  Google Scholar 

  184. Park JG, Sill PC, Makiyi EF, Garcia-Sosa AT, Millard CB, Schmidt JJ, Pang YP (2006) Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A. Bioorg Med Chem 14:395–408

    CAS  PubMed  Google Scholar 

  185. Penner R, Dreyer F (1986) Two different presynaptic calcium currents in mouse motor nerve terminals. Pflugers Arch 406:190–196

    CAS  PubMed  Google Scholar 

  186. Pier CL, Tepp WH, Bradshaw M, Johnson EA, Barbieri JT, Baldwin MR (2008) Recombinant holotoxoid vaccine against botulism. Infect Immun 76:437–442

    CAS  PubMed Central  PubMed  Google Scholar 

  187. Pires-Alves M, Ho M, Aberle KK, Janda KD, Wilson BA (2009) Tandem fluorescent proteins as enhanced FRET-based substrates for botulinum neurotoxin activity. Toxicon 53:392–399

    CAS  PubMed Central  PubMed  Google Scholar 

  188. Potian JG, Thyagarajan B, Hognason K, Lebeda F, Schmidt JJ, McArdle JJ (2010) Investigation of “CRATKML” derived peptides against botulinum neurotoxin A poisoning in vivo and in vitro. Botulinum J 1:407–417

    Google Scholar 

  189. Potter KJ, Bevins MA, Vassilieva EV, Chiruvolu VR, Smith TJ, Smith LA et al. (1998) Production and purification of the heavy chain fragment C of botulinum neurotoxin, serotype B, expressed in the methylotropic yeast Pichia pastoris. Protein Expr Purif 13:1357–1365

    Google Scholar 

  190. Pozsgay M, Michaud C, Liebman M, Orlowski M (1986) Substrate and inhibitor studies of thermolysin-like neutral metalloendopeptidase from kidney membrane fractions. Comparison with bacterial thermolysin. BioChemistry 25:1292–1299

    CAS  PubMed  Google Scholar 

  191. Ramasamy S, Liu CQ, Tran H, Gubala A, Gauci P, McAllister J, Vo T (2010) Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents. Br J Pharmacol 161:721–748

    CAS  PubMed Central  PubMed  Google Scholar 

  192. Raphael BH, Choudoir MJ, Lúquez C, Fernández R, Maslanka SE (2010) Sequence diversity of genes encoding botulinum neurotoxin type F. Appl Environ Microbiol 76:4805–4812

    CAS  PubMed Central  PubMed  Google Scholar 

  193. Ravichandran E, Gong Y, Al-Saleem FH, Ancharski DM, Joshi SG, Simpson LL (2006) An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther 318:1343–1351

    CAS  PubMed  Google Scholar 

  194. Ravichandran E, Al-Saleem FH, Ancharski DM, Elias MD, Singh AK, Shamim M, Gong Y, Simpson LL (2007) Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 75:3043–3054

    CAS  PubMed Central  PubMed  Google Scholar 

  195. Razai A, Garcia-Rodriguez C, Lou J, Geren IN, Forsyth CM, Robles Y, Tsai R, Smith TJ, Smith LA, Siegel RW, Feldhaus M, Marks JD (2005) Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol 351:158–169

    CAS  PubMed  Google Scholar 

  196. Rega PP, Bork CE, Burkholder-Allen K, Bisesi MS, Gold JP (2010) Single-breath count test: an important adjunct in the triaging of patients in a mass-casualty incident due to botulism. Prehosp Disaster Med 25:219–222

    PubMed  Google Scholar 

  197. . Rettig J, Neher E (2002) Emerging roles of presynaptic proteins in Ca + + -triggered exocytosis. Science 298:781–785

    CAS  PubMed  Google Scholar 

  198. Robinson RF, Nahata MC (2003) Management of botulism. Ann Pharmacother 37:127–131

    PubMed  Google Scholar 

  199. Rosetto O, Deloye F, Poulain B, Pellizzari R, Schiavo G, Montecucco C (1995) The metallo-proteinase activity of tetanus and botulinum neurotoxins. J Physiol (Paris) 89:43–50

    Google Scholar 

  200. Roxas-Duncan V, Enyedy I, Montgomery VA, Eccard VS, Carrington MA, Lai H, Gul N, Yang DC, Smith LA (2009) Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A. Antimicrob Agents Chemother 53:3478–3486

    CAS  PubMed Central  PubMed  Google Scholar 

  201. Ruge DR, Dunning FM, Piazza TM, Molles BE, Adler M, Zeytin FN, Tucker WC (2011) Detection of six serotypes of botulinum neurotoxin using fluorogenic reporters. Anal Biochem 411:200–209

    CAS  PubMed  Google Scholar 

  202. Rusnak JM, Smith LA (2009) Botulinum neurotoxin vaccines: past history and recent developments. Hum Vaccin 5:794–805

    CAS  PubMed  Google Scholar 

  203. Sakaba T, Stein A, Jahn R, Neher E (2005) Distinct kinetic changes in neurotransmitter release after SNARE protein cleavage. Science 309:491–494

    CAS  PubMed  Google Scholar 

  204. Schiavo G, Rossetto O, Santucci A, DasGupta BR, Motecucco C (1992) Botulinum neurotoxins are zinc proteins. J Biol Chem 267:23479–23483

    CAS  PubMed  Google Scholar 

  205. Schiavo G, Shone CC, Rosetto O, Alexander FC, Montecucco C (1993) Botulinum neurotoxin F is a zinc endopeptidase specific for VAMP/synaptobrevin. J Biol Chem 268:11516–11519

    CAS  PubMed  Google Scholar 

  206. Schiavo G, Malizio C, Trimble WS, Polverino deLP, Milan G, Sugiyama H, Johnson EA, Montecucco C (1994) Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a single Ala-Ala peptide bond. J Biol Chem 269:20213–20216

    CAS  PubMed  Google Scholar 

  207. Schiavo G, Matteoli M, Montecucco C (2000) Neurotoxins affecting neuroexocytosis. Physiol Rev 80:717–766

    CAS  PubMed  Google Scholar 

  208. Schmidt JJ, Bostian KA (1995) Proteolysis of synthetic peptides by type A botulinum neurotoxin. J Protein Chem 14:703–708

    CAS  PubMed  Google Scholar 

  209. Schmidt JJ, Stafford RG (2002) A high affinity competitive inhibitor of type A botulinum neurotoxin protease activity. FEBS Lett 532:423–426

    CAS  PubMed  Google Scholar 

  210. Schmidt JJ, Stafford RG (2003) Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F. Appl Environ Micobiol 69:297–303

    CAS  Google Scholar 

  211. Schmidt JJ, Stafford RG (2005) Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity. BioChemistry 44:4067–4073

    CAS  PubMed  Google Scholar 

  212. Schmidt JJ, Stafford RG, Bostian KA (1998) Type A botulinum neurotoxin proteolytic activity: development of competitive inhibitors and implication for substrate specificity at the S1’ binding site. FEBS Lett 435:61–64

    CAS  PubMed  Google Scholar 

  213. Schmidt JJ, Stafford RG, Millard CB (2001) High-throughput assays for botulinum neurotoxin proteolytic activity: serotypes A, B, D, and F. Anal Biochem 296:130–137

    CAS  PubMed  Google Scholar 

  214. Segelke B, Knapp M, Kadkhodayan S, Balhorn R, Rupp B (2004) Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: Evidence for noncanonical zinc protease activity. Proc Natl Acad Sci U S A 101:6888–6893

    CAS  PubMed Central  PubMed  Google Scholar 

  215. Shapiro RL, Hatheway C, Swerdlow DL (1998) Botulism in the United States: a clinical and epidemiological review. Ann Intern Med 129:221–228

    CAS  PubMed  Google Scholar 

  216. Sheridan RE, Deshpande SS (1995) Interaction between heavy metal chelators and botulinum neurotoxin at the neuromuscular junction. Toxicon 33:539–549

    CAS  PubMed  Google Scholar 

  217. Sheridan RE, Deshpande SS (1998) Cytotoxicity induced by intracellular zinc chelation in rat cortical neurons. In vitro & Mol Toxicol 11:161–169

    CAS  Google Scholar 

  218. Shi YL, Wang ZF (2004) Cure of experimental botulism and antibotulismic effect of toosendanin. Acta Pharmacol Sin 25:839–848

    CAS  PubMed  Google Scholar 

  219. Shoham D (2000) Iraq’s biological warfare agents: a comprehensive analysis. Crit Rev Microbiol 26:179–204

    CAS  PubMed  Google Scholar 

  220. Shone C, Agostini H, Clancy J, Gu M, Yang H-H, Chu Y, Johnson V, Makie Taal M, McGlashan J, Brehm J, Tong X (2009) Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes. Infect Immun 77:2795–2801

    CAS  PubMed Central  PubMed  Google Scholar 

  221. Siegel LS (1988) Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay. J Clin Microbiol 26:2351–2356

    CAS  PubMed Central  PubMed  Google Scholar 

  222. Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, Degryse RE, Turkel CC, Dodick DW (2013) OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 331:48–56

    CAS  PubMed  Google Scholar 

  223. Šilhár P, Čapková K, Salzameda NT, Barbieri JT, Hixon MS, Janda KD (2010) Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors. J Am Chem Soc 132:2868–2869

    PubMed Central  PubMed  Google Scholar 

  224. Silvaggi NR, Wilson D, Tzipori S, Allen KN (2008) Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex. BioChemistry 47:5736–5745

    CAS  PubMed  Google Scholar 

  225. Simpson LL (1982) The interaction between aminoquinolines and presynaptically acting neurotoxins. J Pharmacol Exp Ther 222:43–48

    CAS  PubMed  Google Scholar 

  226. Simpson LL (1983) Ammonium chloride and methylamine hydrochloride antagonize clostridial neurotoxins. J Pharmacol Exp Ther 225:546–552

    CAS  PubMed  Google Scholar 

  227. Simpson LL (1986) A preclinical evaluation of aminopyridines as putative therapeutic agents in the treatment of botulism. Infect Immun 52:858–862

    CAS  PubMed Central  PubMed  Google Scholar 

  228. Simpson LL (1988) Use of pharmacologic antagonists to deduce commonalities of biologic activity among clostridial neurotoxins. J Pharmacol Exp Ther 245:867–872

    CAS  PubMed  Google Scholar 

  229. Simpson LL (2004) Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 44:167–193

    CAS  PubMed  Google Scholar 

  230. Simpson LL (2007) Balancing the benefits and risks of a botulinum vaccine. Expert Rev Vaccines 6:883–886

    CAS  PubMed  Google Scholar 

  231. Simpson LL, Coffield JA, Bakry N (1993) Chelation of zinc antagonizes the neuromuscular blocking properties of the seven serotypes of botulinum neurotoxin as well as tetanus toxin. J Pharmacol Exp Ther 267:720–727

    CAS  PubMed  Google Scholar 

  232. Simpson LL, Maksymowych AB, Kouguchi H, DuBois G, Bora RS, Joshi S (2005) The role of exoproteases in governing intraneuronal metabolism of botulinum toxin. Protein J 24:155–165

    CAS  PubMed  Google Scholar 

  233. Singh BR (2006) Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting. Neurotox Res 9:73–92

    CAS  PubMed  Google Scholar 

  234. Singh P, Singh MK, Chaudhary D, Chauhan V, Bharadwaj P, Pandey A, Upadhyay N, Dhaked RK (2012) Small-molecule quinolinol inhibitor identified provides protection against BoNT/A in mice. Plos One 7(10):e47110

    CAS  PubMed Central  PubMed  Google Scholar 

  235. Smith LA (1998) Development of recombinant vaccines for botulinum neurotoxin. Toxicon 36:1539–1548

    CAS  PubMed  Google Scholar 

  236. Smith LA, Rusnak JM (2007) Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol 27:303–318

    CAS  PubMed  Google Scholar 

  237. Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, Laporte SL, Tepp WH, Bradshaw M, Johnson EA, Smith LA, Marks JD (2005) Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun 73:5450–5457

    CAS  PubMed Central  PubMed  Google Scholar 

  238. Sobel J (2005) Botulism. Clin Infect Dis 41:1167–1173

    CAS  PubMed  Google Scholar 

  239. Sobel J, Dill T, Kirkpatrick CL, Riek L, Luedtke P, Damrow TA (2009) Clinical recovery and circulating botulinum toxin type F in adult patient. Emerg Infect Dis 15:968–971

    Google Scholar 

  240. Solaja BA, Opsenica D, Smith KS, Milhous WK, Terzić N, Opsenica I, Burnett JC, Nuss J, Gussio R, Bavari S (2008) Novel 4-aminoquinolines active against chloroquine-resistant and sensitive P. falciparum strains that also inhibit botulinum serotype A. J Med Chem 51:4388–4391

    CAS  PubMed  Google Scholar 

  241. Sonnabend O, Sonnabend W, Heinzle R, Sigrist T, Dirnhofer R, Krech U (1981) Isolation of Clostridium botulinum type G and identification of type G botulinal toxin in humans: report of five sudden unexpected deaths. J Infect Dis 143:22–27

    CAS  PubMed  Google Scholar 

  242. Sørensen JB, Matti U, Wei S-H, Nehring RB, Voets T, Ashery U, Binz T, Neher E, Rettig J (2002) The SNARE protein SNAP-25 is linked to fast calcium triggering of exocytosis. Proc. Natl Acad Sci 99:1627–1632

    Google Scholar 

  243. Souayah N, Karim H, Kamin SS, McArdle J, Marcus S (2006) Severe botulism after focal injection of botulinum toxin. Neurology 67:1855–1856

    CAS  PubMed  Google Scholar 

  244. Stahl AM, Adler M, Millard CB, Gilfillan L (2009) Accelerating botulism therapeutic product development in the department of defense. Drug Dev Res 70:303–326

    CAS  Google Scholar 

  245. Stowe GN, Silhár P, Hixon MS, Silvaggi NR, Allen KN, Moe St, Jacobson A, Barbieri JT, Janda KD (2010) Chirality holds the key for potent inhibition of the botulinum neurotoxin serotype A protease. Org Lett 12:756–759

    CAS  PubMed Central  PubMed  Google Scholar 

  246. Sukonpan C, Oost T, Goodnough M, Tepp W, Johnson EA, Rich DH (2004) Synthesis of substrates and inhibitors of botulinum neurotoxin type A metalloprotease. J Pept Res 63:181–193

    CAS  PubMed  Google Scholar 

  247. Swaminathan S (2011) Molecular structures and functional relationships in clostridial neurotoxins. FEBS J 278:4467–4485

    CAS  PubMed  Google Scholar 

  248. Swaminathan S, Eswaramoorthy S (2000) Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol 7:693–699

    CAS  PubMed  Google Scholar 

  249. Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA (1984) Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med 76:794–798

    CAS  PubMed  Google Scholar 

  250. Tang J, Park JG, Millard CB, Schmidt JJ, Pang Y-P (2007) Computer-aided lead optimization: improved small-molecule inhibitor of the zinc endopeptidase of botulinum neurotoxin serotype A. PLoS One 2(8):e761

    PubMed Central  PubMed  Google Scholar 

  251. Thesleff S (1989) Botulinal neurotoxins as tools in studies of synaptic mechanisms. Quart J Exp Physiol 74:1003–1017

    CAS  Google Scholar 

  252. Thompson DE, Brehm JK, Oultram JD, Swinfield TJ, Shone CC, Atkinson T, Melling J, Minton NP (1990) The complete amino acid sequence of the clostridium botulinum type A neurotoxin, deduced by nucleotide sequence analysis of the encoding gene. Eur J Biochem 189:73–81

    CAS  PubMed  Google Scholar 

  253. Thompson AA, Jiao GS, Kim S, Thai A, Cregar-Hernandez L, Margosiak SA, Johnson AT, Han GW, O’Malley S, Stevens RC (2011) Structural characterization of three novel hydroxamate-based zinc chelating inhibitors of the Clostridium botulinum serotype A neurotoxin light chain metalloprotease reveals a compact binding site resulting from 60/70 loop flexibility. BioChemistry 59:4019–4028

    Google Scholar 

  254. Trollet C, Pereira Y, Burgain A, Litzler E, Mezrahi M, Sequin J, Manich M, Popoff MR, Scherman D, Bigey P (2009) Generation of high-titer neutralizing antibodies against botulinum toxins A, B, and E by DNA electrotransfer. Infect Immun 77:2221–2229

    CAS  PubMed Central  PubMed  Google Scholar 

  255. Tsai YC, Maditz R, Kuo CL, Fishman PS, Shoemaker CB, Oyler GA, Weissman AM (2010) Targeting botulinum neurotoxin persistence by the ubiquitin-proteosome system. Proc Natl Acad Sci U S A 107:16554–16559

    CAS  PubMed Central  PubMed  Google Scholar 

  256. Van Heyningen WE, Miller PA (1961) The fixation of tetanus toxin by ganglioside. J Gen Microbiol 24:107–119

    CAS  PubMed  Google Scholar 

  257. Vennerstrom JL, Ager AL Jr, Dorn A, Andersen SL, Gerena L, Ridley RG, Milhous WK (1998) Bisquinolines. 2. Antimalarial N, N-bis(7-chloroquinolin-4-yl)heteroalkanediamines. J Med Chem 41:4360–4364

    CAS  PubMed  Google Scholar 

  258. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M (2010) Synthetic therapeutic peptides: science and market. Drug Discov Today 15:40–56

    Google Scholar 

  259. Vollmer T, Blight AR, Henney HR 3rd (2009) Steady-state pharmacokinetics and tolerability of orally administered famprine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week open-label, follow-up study. Clin Ther 31:2215–2223

    CAS  PubMed  Google Scholar 

  260. Webb RP, Smith LA (2013) What next for vaccine developmemt? Expert Rev Vaccines 12:481–492

    CAS  PubMed  Google Scholar 

  261. Webb RP, Smith TJ, Wright PM, Montgomery VA, Meagher MM, Smith LA (2007) Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins. Vaccine 25:4273–4282

    CAS  PubMed  Google Scholar 

  262. Webb RP, Smith TJ, Wright PM, Brown J, Smith LA (2009) Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1 A2 A3. Vaccine 27:4490–4497

    CAS  PubMed  Google Scholar 

  263. Wein LM, Liu Y (2005) Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. Proc Natl Acad Sci U S A 102:9984–9989

    CAS  PubMed Central  PubMed  Google Scholar 

  264. Wheeler A, Smith HS (2013) Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology 306:124–146

    CAS  PubMed  Google Scholar 

  265. Whelan SM, Elmore MJ, Bodsworth NJ, Atkinson T, Minton NP (1992) The complete amino acid sequence of the Clostridium botulinum type-E neurotoxin derived by nucleotide-sequence analysis of the encoding gene. Eur J Biochem 204:657–667

    CAS  PubMed  Google Scholar 

  266. Wilcox PG, Andolfatto G, Fairbarn MS, Pardy RL (1989) Long-term follow-up of symptoms, pulmonary function, respiratory muscle strength, and exercise performance after botulism. Am Rev Respir Dis 139:157–163

    CAS  PubMed  Google Scholar 

  267. Wilder-Kofie TD, Lúquez C, Adler M, Dykes JK, Coleman JD, Maslanka SE (2011) An alternative in vivo method to refine the mouse bioassay for botulinum toxin detection. Comp Med 61:235–242

    CAS  PubMed Central  PubMed  Google Scholar 

  268. Wileman T, Harding C, Stahl P (1985) Receptor-mediated endocytosis. Biochem J 232:1–14

    CAS  PubMed Central  PubMed  Google Scholar 

  269. Woodruff BA, Griffin PM, McCroskey LM, Smart JF, Wainwright RB, Bryant RG, Hutwagner LC, Hatheway CL (1992) Clinical and laboratory comparison of botulism from toxin type A, B, and E in the United States, 1975–1988. J Infect Dis 166:1281–1286

    CAS  PubMed  Google Scholar 

  270. Xu Q, Pichichero ME, Simpson LL, Elias MD, Smith LA, Zeng M (2009) An adenoviral vector-based mucosal vaccine is effective in protection against botulism. Gene Ther 16:367–375

    PubMed  Google Scholar 

  271. Yamasaki S, Baumeister A, Binz T, Blasi J, Link E, Cornille F, Roques B, Fykse EM, Sudhof TC, Jahn R (1994) Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin. J Biol Chem 269:12764–12772

    CAS  PubMed  Google Scholar 

  272. Yan Z, Chi P, Bibb JA, Ryan TA, Greengard P (2002) Roscovitine: a novel regulator of P/Q-type calcium channels and transmitter release in central neurons. J Physiol (Lond) 540:761–770

    CAS  PubMed Central  Google Scholar 

  273. Yiadom KP, Muhie S, Yang DC (2005) Peptide inhibitors of botulinum neurotoxin by mRNA display. Biochem Biophys Res Commun 335:1247–1253

    CAS  PubMed  Google Scholar 

  274. Yowler BC, Kensinger RD, Schengrund CL (2002) Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I. J Biol Chem 277:32815–32819

    CAS  PubMed  Google Scholar 

  275. Zeng M, Xu Q, Elias MD, Pichichero ME, Simpson LL, Smith LA (2007) Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Vaccine 25:7540–7548

    CAS  PubMed Central  PubMed  Google Scholar 

  276. Zhang P, Ray R, Singh BR, Adler M, Ray P (2009) An efficient drug delivery vehicle for botulism countermeasure. BMC Pharmacol 9:12–19

    PubMed Central  PubMed  Google Scholar 

  277. Zhang S, Wang Y, Qiu S, Dong Y, Xu Y, Jiang D, Fu X, Zhang J, He J, Jia L, Wang L, Zhang C, Sun Y, Song H (2010) Multilocus outbreak of foodborne botulism linked to contaminated sausage in Hebei province, China. Clin Infect Dis 51:322–325

    PubMed  Google Scholar 

  278. Zuniga JE, Schmidt JJ, Fenn T, Burnett JC, Araç D, Gussio R, Stafford RG, Badie SS, Bavari S, Brunger AT (2008) A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate. Structure 16:1588–1597

    CAS  PubMed Central  PubMed  Google Scholar 

  279. Zuniga JE, Hammill JT, Drory O, Nuss JE, Burnett JC, Gussio R, Wipf P, Bavari S, Brunger AT (2010) Iterative structure-based peptide-like inhibitor design against the botulinum neurotoxin serotype A. PLoS One 5(6):e11378

    PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Susan Maslanka, Theresa Smith, Leonard Smith, James Apland, Frank Lebeda, Zygmunt Dembek, Jason Piotrowski, and James Erich Keller for providing insights and useful comments during the writing of this chapter.

Disclaimer

The views expressed in this chapter are those of the authors and do not reflect the official policy of the Department of Army, Department of Defense, or the US Government.

The experimental protocols were approved by the Animal Care and Use Committee at the United States Army Medical Research Institute of Chemical Defense and all procedures were conducted in accordance with the principles stated in the Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966 (P.L. 89–544), as amended.

This research was supported by the Defense Threat Reduction Agency—Joint Science and Technology Office, Medical S&T Division.

Author information

Authors and Affiliations

  1. Neurobehavioral Toxicology Branch, Analytical Toxicology Division, US Army Medical Research Institute of Chemical Defense, 3100 Ricketts Point Road, Aberdeen Proving Ground, MD, 21010, USA

    Michael Adler, Nizamettin Gul & Brian Molles

  2. Medical Devices Industry, Martin, Blanck & Associates, 5203 Leesburg Pike, Falls Church, VA, 22041, USA

    Edward Eitzen

  3. Synaptic Research LLC., 1448 Rolling Road, Catonsville, MD, 21218, USA

    George Oyler

Authors
  1. Michael Adler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nizamettin Gul
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edward Eitzen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. George Oyler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Brian Molles
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Adler .

Editor information

Editors and Affiliations

  1. Units 4-10, Syntaxin Ltd., Abingdon, Oxfordshire, United Kingdom

    Keith A. Foster

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer New York

About this chapter

Cite this chapter

Adler, M., Gul, N., Eitzen, E., Oyler, G., Molles, B. (2014). Prevention and Treatment of Botulism. In: Foster, K. (eds) Molecular Aspects of Botulinum Neurotoxin. Current Topics in Neurotoxicity, vol 4. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9454-6_13

Download citation

Publish with us

Policies and ethics

Search

Navigation